PASG News and Press, Passage Bio Inc. From 03/06/21

Passage Bio, Inc. (PASG) on Friday filed for a common stock offering of up to $125M.The company also filed for a mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.SEC Form S-3Passage Bio shares closed Friday up 2.1% to $...

Today, we take our first in-depth look at Passage Bio. The shares came public a year ago and were just upgraded by Goldman Sachs. The company has a few drug candidates in its pipeline, including three that should begin Phase 1/2 studies soon. A full analysis follows in the pa...

Goldman Sachs analyst Salveen Richter has upgraded shares of Passage Bio, Inc. (PASG) and is increasing his price target to $30 from $28.Richter is optimistic about upcoming phase 1/2 data from gene therapy PBGM01 in GM1 gangliosidosis that is expected mid-year.Richter also expects phase 1/2 ...

Passage Bio, Inc. (PASG) Q4 2020 Earnings Conference Call March 3, 2021 8:30 AM ET Company Participants Stuart Henderson - Vice President of Investor Relations and Strategic Finance Bruce Goldsmith - President and Chief Executive Officer Rich Morris - Chief Financial Officer Gary Romano - Chi...

Passage Bio (PASG): Q4 GAAP EPS of -$0.85 misses by $0.14.Cash, cash equivalents and marketable securities of $304.8M.Press Release For further details see: Passage Bio EPS misses by $0.14

- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease - - Opened first U.S. site for PBGM01’s Imagine-1 global clinical...

PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual invest...

Gain Therapeutics has filed to raise $40 million in a U.S. IPO. The firm is a preclinical biopharma developing treatments for lysosomal storage disorders. GANX has a number of research collaborations, but is still at a very early stage of development, so maybe more relevant for in...

PHILADELPHIA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m...

PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of di...